Cure rates reach up to 86 %
In May 2011 two new drugs, after many years of tests, were finally approved. These tests had shown that these two new breakthrough drugs were highly effective in the treatment of hepatitis C.
The drugs are Incivek (trade name of Telaprevir) and Victrelis (trade name of Boceprevir) .
The two drugs arrived after a gap of twenty years since the last new hepatitis medicine.
The substances, called protease inhibitors, act directly on the virus and prevent its proliferation, different from what has been done up to now; the indirect therapies to combat the viruses, which enable the organism to produce its own defenses.
The new medicines are very similar to each other and will dispute a multi-billion dollar international market.
Both act only against the C virus genotype 1 (the most difficult to treat), and greatly increase the chances of a cure.
The two remedies promise cure rates around 76 % for patients who have never undergone treatment and up to 86 % for those who have been treated and suffered a re-lapse. Those who have had treatment and responded partially have also had their chances increased, as well as non-responders.
The doctor who administers the new drug must choose one of them to be ADDED to conventional treatment with Interferon and Ribavirin. The new drug is not a replacement but an ally in the treatment practiced today.
A BILLIONAIRE MARKET
Hepatitis C is the disease “of the moment”. It is considered the largest epidemic of humanity today.
Around 200 million of the world´s population is suspected of being infected with the virus.
The remedies available nowadays, Interferon and Ribavirin are difficult to tolerate due to their possible side effects.
Besides that the cure rate is on average only 50% of treated cases.
This leads to the obvious need to develop new drugs.
There is now an immense amount of medication (about 800) in studies, some in very advanced stages already.
This fact gives hepatitis patients great encouragement that in the very near future there will be a total cure of the disease with medication much simpler, faster and without side effects.